単純ヘルペスウイルス(HSV)感染症治療薬のパイプライン分析

P&S Market Researchが発行した調査報告書(PSM802105)
◆英語タイトル:Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
◆商品コード:PSM802105
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2017年5月1日
◆ページ数:77
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD1,850 ⇒換算¥209,050見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
Insights on pipeline segments

As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.

New innovating technologies offer development of promising drugs

Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform.

Major companies collaborate for the development of Herpes simplex virus infections Pipeline

The research found that various companies have collaborated for the development of Herpes simplex virus infections pipeline. In June 2014, PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.

Some of the key players developing drugs for the treatment of Herpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and others.

【レポートの目次】

Chapter 1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Route of Administration

1.3.3. Pipeline Analysis by Molecule Type

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1. HSV Infections Therapeutics Overview

4.1.1. Signs and Symptoms

4.1.2. Pathophysiology

4.1.3. Diagnosis

4.1.4. Treatment

4.1.5. Epidemiology

4.2. Key Drivers

4.3. Key Barriers

4.4. HSV Infections Therapeutics Pipeline Analysis

4.4.1. Pipeline Analysis by Phase

4.4.2. Pipeline Analysis by Molecule Type

4.4.3. Pipeline Analysis by Route of Administration

4.4.4. Pipeline Analysis by Company

Chapter 5. HSV Infections Therapeutics Pipeline Analysis by Phase (2017)

5.1. Pre-registration/Registration: Drug Profiles

5.1.1. Pre-Clinical Studies

5.1.2. Clinical Trials

5.1.3. Clinical Results

5.1.4. Strategic Developments

5.1.5. Designations

5.1.6. Grants

5.1.7. Patents

5.1.8. Technology

5.2. Phase III: Drug Profiles

5.2.1. Pre-Clinical Studies

5.2.2. Clinical Trials

5.2.3. Clinical Results

5.2.4. Strategic Developments

5.2.5. Designations

5.2.6. Grants

5.2.7. Patents

5.2.8. Technology

5.3. Phase II: Drug Profiles

5.3.1. Pre-Clinical Studies

5.3.2. Clinical Trials

5.3.3. Clinical Results

5.3.4. Strategic Developments

5.3.5. Designations

5.3.6. Grants

5.3.7. Patents

5.3.8. Technology

5.4. Phase I: Drug Profiles

5.4.1. Pre-Clinical Studies

5.4.2. Clinical Trials

5.4.3. Clinical Results

5.4.4. Strategic Developments

5.4.5. Designations

5.4.6. Grants

5.4.7. Patents

5.4.8. Technology

5.5. Pre-Clinical: Drug Profiles

5.5.1. Pre-Clinical Studies

5.5.2. Strategic Developments

5.5.3. Designations

5.5.4. Grants

5.5.5. Patents

5.5.6. Technology

5.6. Discovery: Drug Profiles

5.6.1. Strategic Developments

5.6.2. Designations

5.6.3. Grants

5.6.4. Patents

5.6.5. Technology

5.7. Inactive: Drug Profiles

5.7.1. Pre-Clinical Studies

5.7.2. Clinical Trials

5.7.3. Clinical Results

5.7.4. Strategic Developments

5.7.5. Designations

5.7.6. Grants

5.7.7. Patents

5.7.8. Technology

5.8. Discontinued: Drug Profiles

5.8.1. Pre-Clinical Studies

5.8.2. Clinical Trials

5.8.3. Clinical Results

5.8.4. Strategic Developments

5.8.5. Designations

5.8.6. Grants

5.8.7. Patents

5.8.8. Technology

Chapter 6. Clinical Trials Analysis

6.1. Clinical Trials by Region

6.2. Clinical Trials by Trial Status

Chapter 7. Competitive Landscape Analysis

7.1. Key Players Benchmarking

7.2. SWOT Analysis

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.



【レポートのキーワード】

単純ヘルペスウイルス(HSV)感染症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 単純ヘルペスウイルス(HSV)感染症治療薬のパイプライン分析(Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆